American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product

Company's innovative new ASAP Wound Dressing Gel is now approved as a 510(k) medical device "for the topical management of minor cuts, lacerations, abrasions, 1st and 2nd degree burns, and skin irritations" 


SALT LAKE CITY, April 14  /PRNewswire-FirstCall/ -- American Biotech Labs, LLC (ABL), developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(R), today announced that the company has been granted formal approval by the U.S. Food and Drug Administration (FDA) to market its ASAP Wound Dressing Gel throughout the United States. Clifton Mining Company is a major shareholder in American Biotech Labs.

The FDA 510(k) medical device approval letter confirms that ABL may market ASAP Wound Dressing Gel "for the topical management of minor cuts, lacerations, abrasions, 1st and 2nd degree burns, and skin irritations." The product utilizes ABL's innovative SilverSol Technology, which has garnered multiple patents in the U.S. and several countries throughout the world, including a broad-use patent that provides the company with exclusive rights to use its silver-based products to combat many of the world's most destructive pathogens, including malaria, tuberculosis, MRSA and HIV.

"We are delighted with the FDA's decision to grant approval for ABL to broadly market our ASAP Wound Dressing Gel," said Dr. William Moeller, a managing director of American Biotech Labs. "We feel this is a singularly effective wound care product, and it is a tremendous validation for us that ABL products have now received approval from the FDA as well as from the EPA."

ABL has performed extensive anti-microbial studies against bacteria, yeast, fungus and other pathogens. Information about these studies is available at research section of the ABL Website, http://www.americanbiotechlabs.com/researchprotected/researchmenu.html.

About American Biotech Labs

American Biotech Labs (ABL; http://www.americanbiotechlabs.com/), founded in 1998, utilizes patented processes and SilverSol Technology(R) to create singularly powerful and effective nano-catalytic silver products. In extensive testing performed by a variety of respected laboratories and researchers, ABL's silver hydrosol has consistently demonstrated the ability, without any known toxic side effects, to destroy a wide range of bacteria, viruses, yeast, and molds. ABL products have been approved by the Environmental Protection Agency (EPA) as a disinfectant for dental water lines, and as a surface disinfectant for bacteria, yeast and mold in hospital, residential, commercial and industrial settings; and by the U.S. Food and Drug Administration (FDA) for wound care. The company's products have been the subject of multiple peer-reviewed articles in professional journals, and are sold worldwide at health food stores and by medical professionals under the Silver Biotics(R) and ASAP Solution(R) brands, and through a variety of private labels.

About Clifton Mining

Clifton trades on the U.S. OTC: (CFTN). For additional information, contact Dr. Ken Friedman (president) at 303-642-0659 or Keith Moeller (vice president) at 801-756-1414, or see our Website at http://www.cliftonmining.com/.

Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company's business prospects and performance.

  Press Contact:

  Kimball Thomson
  Next Phase Communications (for American Biotech Labs)
  
  801.918.3637


DATASOURCE: Clifton Mining Company



CONTACT:  Kimball Thomson of Next Phase Communications, [phone],

, for American Biotech Labs/Clifton Mining Company



Web Site:  http://www.cliftonmining.com/

http://www.americanbiotechlabs.com/

http://www.americanbiotechlabs.com/researchprotected/researchmenu.html 

Copyright